ClinicalTrials.gg
CompletedNCT07856849PRECISEUpdated Oct 5, 2026

The Effect of Capsulotomy Size on Effective Lens Position in Robotic Laser Cataract Surgery

An interventional study of Femtosecond Laser Capsulotomy - Small Size (4.6 mm) and Femtosecond Laser Capsulotomy - Large Size (5.6 mm) in Cataract Surgery, Intraocular Lens Position and Refractive Outcomes After Cataract Surgery, sponsored by Twin Cities Eye Consultants. Completed at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Twin Cities Eye Consultants · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Oct 2025, registered Sep 2026).
Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 456 studies in Cataract with a site in United States — 49 open to participants now, 56 under way, 4 of them phase 3. Cataract · United States.

Enrollment
281st of 322
20 · median 100
Started
2025
with 23 others
No phase
150 of 456
17 open now
Registered
453rd of 456
by date

Among the 456 studies in Cataract with a site in United States, this one is the 281st largest by enrollment of the 322 interventional ones that give a count, is one of 24 that started in 2025, is one of 150 with no phase, and was the 453rd registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

49 of the 456 studies in Cataract with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 456 studies in Cataract with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether the size of the opening made during laser-assisted cataract surgery affects where the artificial lens sits in the eye and the glasses prescription after surgery.

This study includes adults aged 40 years and older who are scheduled to have cataract surgery in both eyes. Cataract surgery removes the cloudy natural lens of the eye and replaces it with a clear artificial lens, called an intraocular lens.

The main questions this study aims to answer are:

  • Does the size of the capsulotomy (the circular opening made during surgery) affect the final position of the lens implant?
  • Does capsulotomy size affect vision or glasses prescription after surgery?

Each participant will receive two different capsulotomy sizes, one in each eye. The size (big or small) used in each eye is chosen by chance. Both sizes are safe and commonly used during cataract surgery. All surgeries use a laser system that allows the opening to be made very precisely.

Participants will:

  • Attend one study visit before surgery for eye exams and imaging
  • Undergo standard cataract surgery in both eyes using laser assistance
  • Attend one final study visit about 12 weeks after the second surgery for repeat eye exams and imaging

Participants will receive the same type of lens implant and standard follow-up care whether or not they join the study. There is no direct benefit from taking part. The information learned may help doctors improve planning and accuracy for future cataract surgeries.

Read the detailed description

Accurate prediction of effective lens position (ELP) is a critical factor in achieving optimal refractive outcomes following cataract surgery. Even small variations in the postoperative position of an intraocular lens (IOL) can influence refractive accuracy and patient satisfaction. One surgical factor that may contribute to ELP variability is the size of the anterior capsulotomy, which affects IOL centration, capsular overlap, and long-term stability within the capsular bag.

The PRECISE study is a prospective, randomized, within-subject clinical investigation designed to evaluate the effect of capsulotomy size on postoperative effective lens position and refractive outcomes in patients undergoing femtosecond laser-assisted cataract surgery. By using a paired-eye design, each participant serves as their own control, thereby minimizing inter-individual variability related to ocular anatomy, wound healing, and biometric differences.

All surgical procedures are performed using the LENSAR ALLY® femtosecond laser system, which allows for highly precise, reproducible, and well-centered capsulotomies. Two different capsulotomy sizes are used in this study, 4.6 mm and 5.6 mm, both of which fall within accepted standards of care and are commonly employed in routine cataract surgery. Capsulotomy size assignment is randomized between eyes. Aside from capsulotomy size, all other aspects of the surgical procedure, including IOL model and surgical technique, remain consistent with standard clinical practice.

Participants undergo comprehensive preoperative evaluation, including visual acuity testing, ocular biometry, optical coherence tomography imaging, and slit-lamp examination. These assessments are repeated at a final postoperative study visit approximately 12 weeks after the second eye surgery to evaluate lens position and refractive status. Standard postoperative follow-up visits required for routine cataract care are conducted separately and are not altered by study participation.

The study focuses on detecting subtle differences in effective lens position and refractive outcomes that may be associated with capsulotomy size. Any anticipated differences in ELP are expected to be small and unlikely to result in clinically noticeable visual changes for participants. However, identifying consistent trends may provide insight into the role of capsulotomy geometry in IOL behavior and help refine IOL power calculations, surgical planning, and refractive predictability in future cataract surgery patients.

No experimental devices or medications are used in this study. All participants receive standard monofocal intraocular lenses and routine perioperative care. The risks associated with participation are consistent with those of standard cataract surgery, and no additional study-specific risks are anticipated.

Overall, this study aims to contribute to a better understanding of the relationship between femtosecond laser capsulotomy size and postoperative lens position, with the long-term goal of improving precision and outcomes in cataract surgery.

03

Conditions studied

  • Cataract Surgery
  • Intraocular Lens Position
  • Refractive Outcomes After Cataract Surgery
  • Cataract

Browse trials for

Keywords

  • Cataract Surgery
  • Femtosecond Laser-Assisted Cataract Surgery
  • Capsulotomy Size
  • Effective Lens Position
  • Intraocular Lens Implantation
  • Refractive Outcomes
  • Laser Capsulotomy
  • Monofocal Intraocular Lens
  • LENSAR ALLY Laser
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 40 years or older
  • General ocular health sufficient to allow accurate biometry and visual outcome measurements
  • Candidates for femtosecond laser-assisted cataract surgery using the LENSAR ALLY® system
  • Best-corrected visual acuity (BCVA) of 20/70 or better in both eyes
  • Visual impairment primarily attributable to cataract
  • Dilated pupil size of at least 7.5 mm in both eyes
  • Scheduled for bilateral cataract surgery with standard postoperative care
  • Eligible for implantation of a monofocal ZCB00 intraocular lens (Johnson \& Johnson Vision) in both eyes
  • Ability to read and understand the form in English
  • Willingness and ability to comply with all study procedures and follow-up visits, including the 12-week postoperative visit
  • Ability to provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Anatomically narrow angles at high risk of occlusion from pharmacologic dilation
  • ocular pathology other than cataract that may compromise study outcomes
  • History of clinically significant ocular inflammation or infection within 6 months prior to screening
  • History of corneal transplant or clinically significant corneal dystrophy, including Fuchs' dystrophy with 12 or more confluent guttae
  • History of prior corneal refractive surgery, including RK, LASIK, or PRK
  • Complicated cataracts, including mature, hypermature, or traumatic cataracts
  • Uncontrolled systemic disease that may place the participant at risk or prevent study completion
  • Inability to follow instructions or physically comply with imaging or positioning requirements
  • Intraoperative complications such as posterior capsule rupture, vitreous loss, or zonular dehiscence
  • Known allergy or sensitivity to perioperative medications or study-related materials
  • Inability to provide or comply with study procedures
  • Participation in another drug or device clinical trial within 30 days prior to enrollment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Small Capsulotomy Size (4.6 mm)

    Participants will receive femtosecond laser-assisted cataract surgery with a smaller capsulotomy size (4.6 mm) created using the LENSAR ALLY laser system. This capsulotomy size is within standard clinical practice and is randomly assigned to one eye.

    Procedure: Femtosecond Laser Capsulotomy - Small Size (4.6 mm)

  • Experimental
    Large Capsulotomy Size (5.6 mm)

    Participants will receive femtosecond laser-assisted cataract surgery with a larger capsulotomy size (5.6 mm) created using the LENSAR ALLY laser system. This capsulotomy size is within standard clinical practice and is randomly assigned to the contralateral eye.

    Procedure: Femtosecond Laser Capsulotomy - Large Size (5.6 mm)

Interventions

  • ProcedureFemtosecond Laser Capsulotomy - Small Size (4.6 mm)

    Femtosecond laser-assisted cataract surgery in which a smaller capsulotomy (4.6 mm) is created using the LENSAR ALLY laser system. The capsulotomy size is within standard clinical practice and is randomly assigned to one eye. All other aspects of cataract surgery, including intraocular lens implantation and postoperative care, follow routine clinical standards.

    Also known as: LENSAR ALLY Laser Capsulotomy (Small), 4.6 mm

  • ProcedureFemtosecond Laser Capsulotomy - Large Size (5.6 mm)

    Femtosecond laser-assisted cataract surgery in which a larger capsulotomy (5.6 mm) is created using the LENSAR ALLY laser system. The capsulotomy size is within standard clinical practice and is randomly assigned to the contralateral eye. All other aspects of cataract surgery, including intraocular lens implantation and postoperative care, follow routine clinical standards.

    Also known as: LENSAR ALLY Laser Capsulotomy (Large), 5.6 mm

06

What researchers measure

Primary outcomes

  1. Anterior Chamber Depth (ACD)

    Difference in anterior chamber depth (ACD) between eyes receiving a 4.6 mm femtosecond laser capsulotomy and eyes receiving a 5.6 mm femtosecond laser capsulotomy. ACD will be measured using standard optical biometry to assess the final position of the implanted monofocal intraocular lens.

    Time frame: 12 weeks after second eye surgery

Secondary outcomes

  1. Refractive Accuracy (MRSE vs Target Refraction)

    Difference between the manifest refraction spherical equivalent (MRSE) and the intended target refraction for each eye following cataract surgery, comparing eyes with different capsulotomy sizes.

    Time frame: 12 weeks after second eye surgery

  2. Residual Refractive Error Distribution

    Percentage of eyes within ±0.25 D, ±0.50 D, ±0.75 D, and ±1.00 D of target refraction following cataract surgery, comparing eyes receiving a 4.6 mm versus a 5.6 mm capsulotomy.

    Time frame: 12 weeks after second eye surgery

  3. Distance Visual Acuity Outcomes

    Uncorrected distance visual acuity (UDVA) and best-corrected distance visual acuity (BCVA) following cataract surgery, reported as the percentage of eyes achieving visual acuity thresholds of 20/20, 20/25, 20/32, 20/40, and 20/60 or worse, comparing eyes with different capsulotomy sizes.

    Time frame: 12 weeks after second eye surgery

07

Study locations

1 site
  • Twin Cities Eye Consultants, Coon Rapids, Minnesota 55433
    Coon Rapids, Minnesota 55433, United States
08

References and documents

Publications

  • Lee JH, Lee YE, Joo CK. Clinical results of the open ring PMMA guider assisted capsulorrhexis in cataract surgery. BMC Ophthalmol. 2018 May 10;18(1):116. doi: 10.1186/s12886-018-0782-6. PubMed 29747619 ↗
  • Sharma B, Abell RG, Arora T, Antony T, Vajpayee RB. Techniques of anterior capsulotomy in cataract surgery. Indian J Ophthalmol. 2019 Apr;67(4):450-460. doi: 10.4103/ijo.IJO_1728_18. PubMed 30900573 ↗
  • Zhu Y, Shi K, Yao K, Wang Y, Zheng S, Xu W, Chen P, Yu Y, Shentu X. Parameters of Capsulorrhexis and Intraocular Lens Decentration After Femtosecond and Manual Capsulotomies in High Myopic Patients With Cataracts. Front Med (Lausanne). 2021 Mar 11;8:640269. doi: 10.3389/fmed.2021.640269. eCollection 2021. PubMed 33777981 ↗
  • Packer M, Teuma EV, Glasser A, Bott S. Defining the ideal femtosecond laser capsulotomy. Br J Ophthalmol. 2015 Aug;99(8):1137-42. doi: 10.1136/bjophthalmol-2014-306065. Epub 2015 Mar 31. PubMed 25829488 ↗
  • Li S, Hu Y, Guo R, Shao Y, Zhao J, Zhang J, Wang J. The effects of different shapes of capsulorrhexis on postoperative refractive outcomes and the effective position of the intraocular lens in cataract surgery. BMC Ophthalmol. 2019 Feb 21;19(1):59. doi: 10.1186/s12886-019-1068-3. PubMed 30791880 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Mar 2026, 4 months.

Of 304 non-industry interventional studies with no phase under Cataract, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's 4 months is below that.

Counting every sponsor, half of 494 studies reached it within 17 months; a quarter within 9 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 5, 2026
StartActual
Oct 27, 2025
Primary completionActual
Mar 6, 2026
CompletionActual
Mar 6, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856849
Lead sponsor
Twin Cities Eye Consultants
Collaborators
LensAR Incorporated
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Oct 27, 2025
Primary completion
Mar 6, 2026
Completion
Mar 6, 2026
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion